The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study finds.

GLP-1 weight-loss drugs are changing how people date and connect. In a nationally representative survey of 2,000 single U.S.

As a result, estimated annual spending on GLP-1 drugs among non-diabetics rose from $1.6 billion between 2018 and 2021 to $5.8 billion in 2022, the study showed.

A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...

People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new ...

A new study reports that of the 1 million new GLP-1 medication users identified between 2011 to 2023, there was a twofold increase in GLP-1 medication users who do not have type 2 diabetes.

"Our findings also show that while the benefits of GLP-1 drugs are significant, their use does come with some added risk of diabetic retinopathy, suggesting that physicians need to carefully ...

A new study reports that GLP-1 medications may improve low testosterone in men with obesity or type 2 diabetes. The findings ...

Overpaying for GLP-1 medications is extremely common, with a new data analysis of 102,166 drugs showing that 92% of those prescriptions could have been filled at a lower price. The DoseSpot analysis ...

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences.

No cancers had statistically significant adverse associations with GLP-1 use, he noted, including pancreatic cancer (HR 1.00, 95% CI 0.83-1.20) and thyroid cancer (HR 1.02, 95% CI 0.83-1.25 ...

Study shows shift in GLP-1 drug use for obesity, not diabetes. Dennis Thompson, HealthDay News. Tue, July 23, 2024 at 5:58 PM UTC. 2 min read.